Press & Events
Hyperion Therapeutics Elects David W. Gryska to Board of Directors
Hyperion Therapeutics’ Glycerol Phenylbutyrate Meets Primary Endpoint in Phase III Pivotal Study in Urea Cycle Disorders
Hyperion Therapeutics Receives FDA Fast Track Designation for Glycerol Phenylbutyrate for the Treatment of Urea Cycle Disorders
Hyperion Therapeutics to Present at Needham Healthcare Conference
Hyperion Therapeutics Announces First Patient Enrolled in Pivotal Trial in Patients With Urea Cycle Disorders
Hyperion Therapeutics Raises $60 Million Series C Funding
Hyperion Therapeutics Announces Results of Phase I Study in Patients with Liver Cirrhosis
Hyperion Therapeutics Receives Special Protocol Assessment Approval from FDA for Pivotal Phase III Trial in Urea Cycle Disorders
Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting with FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients with Urea Cycle Disorders
Archived Press
2013
MayApril
March
February
January
2012
DecemberNovember
October
September
August
July
June
May
April
March
February
January